Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554515 | 1.00 | DPP4 (1.00) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL4074251 | 0.97 | DPP4 (0.94) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL556204 | 0.95 | DPP4 (0.90) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL4667057 | 0.95 | DPP4 (0.90) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL4667712 | 0.95 | DPP4 (0.90) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL555374 | 0.94 | DPP4 (0.89) | DPP4ALDH1A1TSHRLMNAMAPT | |
| Hydrochloric Acid SCHEMBL5339031 | 0.94 | DPP4 (0.88) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL555521 | 0.92 | DPP4 (0.85) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL555972 | 0.92 | DPP4 (0.85) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL556913 | 0.92 | DPP4 (0.85) | DPP4ALDH1A1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017184788-A1 | ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE, AND RELATED COMPOUNDS IN HUMANS | Keto Patent Group, Inc. (US) | 2017-10-26 | — | — | WO | claimed |
| US-20170296501-A1 | ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE, AND RELATED COMPOUNDS IN HUMANS | AXCESS GLOBAL SCIENCES, LLC | 2017-10-19 | — | — | US | claimed |
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | claimed |
| US-20240226043-A1 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | AXCESS GLOBAL SCIENCES, LLC | 2024-07-11 | — | — | US | disclosed |
| US-11969411-B2 | Administration of berberine metabolites | AXCESS GLOBAL SCIENCES, LLC (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3445355-B1 | BETA-HYDROXYBUTYRATE FOR USE IN NON-THERAPEUTIC METHODS OF CONTROLLING WEIGHT LOSS AND KETOTIS | AXCESS GLOBAL SCIENCES LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230364042-A1 | ADMINISTRATION OF BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS FOR THE TREATMENT AND/OR PREVENTION OF RESPIRATORY ILLNESSES | AXCESS GLOBAL SCIENCES, LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230346723-A1 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS | AXCESS GLOBAL SCIENCES, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230346699-A1 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN VETERINARY APPLICATIONS | AXCESS GLOBAL SCIENCES, LLC | 2023-11-02 | — | — | US | disclosed |
| WO-2023212326-A1 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN VETERINARY APPLICATIONS | AXCESS GLOBAL SCIENCES, LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212319-A1 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE SALT BLEND AND RELATED COMPOUNDS IN HUMANS | AXCESS GLOBAL SCIENCES, LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS B (DK) | 2005-07-07 | — | — | US | disclosed |
| US-6869947-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| WO-2004035773-A1 | IMMOBILIZATION OF COMPOUNDS ON POLYMERIC MATRIX | ENZYMOTEC LTD. (IL) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| EP-1404675-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | DPP4 1/4885ALDH1A1 176/4885TSHR 3409/4885 |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | DPP4 1/4885ALDH1A1 55/4885TSHR 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.